Compare Stocks

Date Range: 

 Revance TherapeuticsMorphicAtea PharmaceuticalsCytokineticsIronwood Pharmaceuticals
SymbolNASDAQ:RVNCNASDAQ:MORFNASDAQ:AVIRNASDAQ:CYTKNASDAQ:IRWD
Price Information
Current Price$29.72$64.71$31.97$33.61$12.99
50-Day Moving Average$27.90$60.83$28.24$30.98$12.97
52-Week Low$22.89$24.52$18.72$14.71$8.63
52-Week High$33.83$93.00$94.17$34.45$14.27
MarketRank™
Overall Score2.22.62.62.41.8
Analysis Score3.53.53.54.51.1
Community Score4.54.35.05.04.1
Dividend Score0.00.00.00.00.0
Ownership Score2.55.02.52.50.8
Earnings & Valuation Score0.60.01.90.03.1
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyHold
Consensus Price Target$37.25$85.00$55.75$43.09$12.00
% Upside from Price Target25.34% upside31.36% upside74.38% upside28.21% upside-7.62% downside
Trade Information
Market Cap$2.13 billion$2.36 billion$2.40 billion$2.81 billion$2.12 billion
Beta1.241.2N/A1.411.37
Average Volume421,589274,1761,504,6031,218,4021,938,897
Sales & Book Value
Annual Revenue$15.32 million$44.94 million$48.63 million$55.83 million$389.52 million
Price / Sales139.3552.4954.4250.285.43
CashflowN/AN/AN/AN/A$0.87 per share
Price / CashN/AN/AN/AN/A14.93
Book Value$5.62 per share$4.66 per share$6.63 per share$1.60 per share$0.39 per share
Price / Book5.2913.894.8221.0133.31
Profitability
Net Income$-282,090,000.00$-45,000,000.00$-10,950,000.00$-127,290,000.00$106.18 million
EPS($4.86)($1.47)($0.51)($1.97)$0.79
Trailing P/E RatioN/AN/AN/AN/A4.16
Forward P/E RatioN/AN/A2.23N/A7.55
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-644.56%-158.61%N/A-269.48%123.20%
Return on Equity (ROE)-103.06%-24.79%N/A-179.39%109.74%
Return on Assets (ROA)-44.14%-18.05%N/A-28.99%28.51%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio1.50%N/AN/A7.76%0.64%
Current Ratio6.09%12.51%3.18%5.90%4.62%
Quick Ratio6.00%12.51%3.18%5.90%4.62%
Ownership Information
Institutional Ownership Percentage75.29%71.77%70.41%90.54%N/A
Insider Ownership Percentage4.40%31.40%18.40%5.70%12.60%
Miscellaneous
Employees4708939184232
Shares Outstanding71.83 million36.45 million82.78 million83.51 million162.90 million
Next Earnings Date11/8/2021 (Estimated)11/8/2021 (Estimated)12/9/2021 (Estimated)11/3/2021 (Estimated)11/4/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableOptionableOptionable
SourceHeadline
Interesting IRWD Put And Call Options For May 2022Interesting IRWD Put And Call Options For May 2022
nasdaq.com - September 17 at 3:46 PM
Oversold Conditions For Ironwood Pharmaceuticals (IRWD)Oversold Conditions For Ironwood Pharmaceuticals (IRWD)
nasdaq.com - September 14 at 8:57 PM
Ironwood Pharmaceuticals Inc (IRWD): Price Now Near $12.4; Daily Chart Shows An Uptrend on 100 Day BasisIronwood Pharmaceuticals Inc (IRWD): Price Now Near $12.4; Daily Chart Shows An Uptrend on 100 Day Basis
etfdailynews.com - September 10 at 4:48 PM
Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Gap Down to $12.56Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Gap Down to $12.56
americanbankingnews.com - September 8 at 10:58 AM
Ironwood Pharma: FDA Approves Revised Label For LINZESS - Quick FactsIronwood Pharma: FDA Approves Revised Label For LINZESS - Quick Facts
nasdaq.com - August 26 at 10:41 AM
Ironwood Irritable-Bowel Drug Gets Revised FDA Warning LabelIronwood Irritable-Bowel Drug Gets Revised FDA Warning Label
finance.yahoo.com - August 26 at 10:41 AM
Ironwood Pharmaceuticals Announces FDA Approval of Revised LINZESS® (linaclotide) LabelIronwood Pharmaceuticals Announces FDA Approval of Revised LINZESS® (linaclotide) Label
finance.yahoo.com - August 26 at 10:41 AM
Sarissa Capital Management LP Buys Alkermes PLC, Vor Biopharma Inc, Sells BioCryst ...Sarissa Capital Management LP Buys Alkermes PLC, Vor Biopharma Inc, Sells BioCryst ...
uk.finance.yahoo.com - August 24 at 3:45 PM
Ironwood Pharmaceuticals, Inc. Class A Common Stock (IRWD)Ironwood Pharmaceuticals, Inc. Class A Common Stock (IRWD)
nasdaq.com - August 24 at 9:17 AM
Noteworthy Tuesday Option Activity: PRPL, IRWD, STLDNoteworthy Tuesday Option Activity: PRPL, IRWD, STLD
nasdaq.com - August 10 at 5:45 PM
Ironwoods (IRWD) Q2 Earnings Beat, 2021 Guidance RaisedIronwood's (IRWD) Q2 Earnings Beat, 2021 Guidance Raised
finance.yahoo.com - August 6 at 1:56 PM
Ironwood Pharmaceuticals, inc (IRWD) Q2 2021 Earnings Call TranscriptIronwood Pharmaceuticals, inc (IRWD) Q2 2021 Earnings Call Transcript
finance.yahoo.com - August 5 at 7:46 PM
Ironwood: Q2 Earnings SnapshotIronwood: Q2 Earnings Snapshot
sfgate.com - August 5 at 9:45 AM
Ironwood Pharmaceuticals Reports Strong Second-Quarter 2021 Results, Raises Full-Year GuidanceIronwood Pharmaceuticals Reports Strong Second-Quarter 2021 Results, Raises Full-Year Guidance
finance.yahoo.com - August 5 at 9:45 AM
Why Ironwood (IRWD) Could Beat Earnings Estimates AgainWhy Ironwood (IRWD) Could Beat Earnings Estimates Again
msn.com - August 4 at 1:30 PM
Ironwood Pharmaceuticals Appoints John Minardo as Chief Legal OfficerIronwood Pharmaceuticals Appoints John Minardo as Chief Legal Officer
finance.yahoo.com - August 3 at 12:05 PM
Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) Is An Exciting Stock To Watch.Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) Is An Exciting Stock To Watch.
stocksregister.com - July 23 at 12:54 PM
Ironwood Pharmaceuticals to Host Second Quarter 2021 Investor Update CallIronwood Pharmaceuticals to Host Second Quarter 2021 Investor Update Call
finance.yahoo.com - July 22 at 8:01 PM
Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD): How Much Is It Worth And What Should Investors Do?Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD): How Much Is It Worth And What Should Investors Do?
marketingsentinel.com - July 22 at 3:00 PM
We Think Ironwood Pharmaceuticals (NASDAQ:IRWD) Can Manage Its Debt With EaseWe Think Ironwood Pharmaceuticals (NASDAQ:IRWD) Can Manage Its Debt With Ease
finance.yahoo.com - July 21 at 1:10 PM
Ironwood Pharmaceuticals Inc. [IRWD] gain 9.13% so far this year. What now?Ironwood Pharmaceuticals Inc. [IRWD] gain 9.13% so far this year. What now?
dbtnews.com - July 13 at 11:53 AM
Is Ironwood Pharmaceuticals, Inc. (IRWD) A Good Stock To Buy?Is Ironwood Pharmaceuticals, Inc. (IRWD) A Good Stock To Buy?
finance.yahoo.com - July 12 at 6:07 PM
12-month price target for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) now sits at $1512-month price target for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) now sits at $15
marketingsentinel.com - July 8 at 1:36 PM
Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) Recovered 34.12% From The 52-Week Low, And Now It’s 12.47% YTD – This Is What You Do NowIronwood Pharmaceuticals Inc. (NASDAQ: IRWD) Recovered 34.12% From The 52-Week Low, And Now It’s 12.47% YTD – This Is What You Do Now
marketingsentinel.com - June 25 at 2:09 PM
For Ironwood Pharmaceuticals Inc. [IRWD], Analyst sees a drop to $9. What next?For Ironwood Pharmaceuticals Inc. [IRWD], Analyst sees a drop to $9. What next?
dbtnews.com - June 24 at 12:43 AM
DateCompanyBrokerageAction
9/9/2021Atea PharmaceuticalsSVB Leerink
Initiated Coverage
9/7/2021CytokineticsBarclays
Boost Price Target
8/18/2021Atea PharmaceuticalsMorgan Stanley
Boost Price Target
8/9/2021CytokineticsPiper Sandler
Lower Price Target
8/6/2021Revance TherapeuticsBarclays
Boost Price Target
8/6/2021CytokineticsHC Wainwright
Boost Price Target
7/20/2021CytokineticsCantor Fitzgerald
Boost Price Target
7/20/2021CytokineticsBarclays
Boost Price Target
7/19/2021CytokineticsJMP Securities
Boost Price Target
7/19/2021CytokineticsRaymond James
Boost Price Target
7/19/2021CytokineticsPiper Sandler
Boost Price Target
7/19/2021CytokineticsHC Wainwright
Boost Price Target
7/19/2021CytokineticsNeedham & Company LLC
Boost Price Target
7/16/2021Ironwood PharmaceuticalsMorgan Stanley
Boost Price Target
7/6/2021Ironwood PharmaceuticalsNorthland Securities
Reiterated Rating
7/1/2021CytokineticsMizuho
Initiated Coverage
6/3/2021Atea PharmaceuticalsMorgan Stanley
Lower Price Target
5/11/2021Revance TherapeuticsMizuho
Lower Price Target
5/11/2021CytokineticsMizuho
Boost Price Target
5/3/2021MorphicBMO Capital Markets
Lower Price Target
4/23/2021Revance TherapeuticsMizuho
Boost Price Target
4/19/2021CytokineticsMorgan Stanley
Boost Price Target
4/14/2021Revance TherapeuticsNeedham & Company LLC
Reiterated Rating
4/6/2021Atea PharmaceuticalsMorgan Stanley
Boost Price Target
3/11/2021CytokineticsWolfe Research
Initiated Coverage
3/1/2021MorphicWells Fargo & Company
Boost Price Target
2/25/2021Ironwood PharmaceuticalsMorgan Stanley
Lower Price Target
2/23/2021Revance TherapeuticsMizuho
Boost Price Target
2/23/2021Revance TherapeuticsHC Wainwright
Boost Price Target
2/18/2021CytokineticsBarclays
Initiated Coverage
2/2/2021MorphicRoyal Bank of Canada
Boost Price Target
1/29/2021Atea PharmaceuticalsJPMorgan Chase & Co.
Boost Price Target
1/20/2021CytokineticsHC Wainwright
Boost Price Target
1/8/2021Revance TherapeuticsNeedham & Company LLC
Boost Price Target
12/16/2020CytokineticsMorgan Stanley
Boost Price Target
12/14/2020CytokineticsMizuho
Lower Price Target
11/24/2020Atea PharmaceuticalsEvercore ISI
Initiated Coverage
11/24/2020Atea PharmaceuticalsMorgan Stanley
Initiated Coverage
11/24/2020Atea PharmaceuticalsJPMorgan Chase & Co.
Initiated Coverage
11/24/2020Atea PharmaceuticalsWilliam Blair
Initiated Coverage
11/24/2020CytokineticsRaymond James
Reiterated Rating
11/23/2020CytokineticsHC Wainwright
Lower Price Target
11/16/2020CytokineticsNeedham & Company LLC
Reiterated Rating
11/16/2020CytokineticsMorgan Stanley
Lower Price Target
11/10/2020Revance TherapeuticsMizuho
Lower Price Target
11/6/2020Ironwood PharmaceuticalsCredit Suisse Group
Boost Price Target
11/6/2020Ironwood PharmaceuticalsMorgan Stanley
Boost Price Target
10/28/2020CytokineticsThe Goldman Sachs Group
Initiated Coverage
10/26/2020Revance TherapeuticsBarclays
Boost Price Target
10/26/2020MorphicRoyal Bank of Canada
Initiated Coverage
10/15/2020Revance TherapeuticsNeedham & Company LLC
Boost Price Target
10/15/2020Revance TherapeuticsHC Wainwright
Boost Price Target
10/12/2020CytokineticsMorgan Stanley
Lower Price Target
10/8/2020CytokineticsHC Wainwright
Lower Price Target
9/30/2020Ironwood PharmaceuticalsWells Fargo & Company
Downgrade
9/28/2020Revance TherapeuticsBarclays
Boost Price Target
8/26/2020MorphicBMO Capital Markets
Reiterated Rating
8/11/2020Revance TherapeuticsMizuho
Initiated Coverage
8/11/2020MorphicBMO Capital Markets
Boost Price Target
8/7/2020Ironwood PharmaceuticalsMorgan Stanley
Boost Price Target
8/3/2020Ironwood PharmaceuticalsNorthland Securities
Reiterated Rating
7/15/2020Ironwood PharmaceuticalsMorgan Stanley
Lower Price Target
7/10/2020Revance TherapeuticsHC Wainwright
Reiterated Rating
7/5/2020MorphicBMO Capital Markets
Reiterated Rating
6/17/2020Ironwood PharmaceuticalsNorthland Securities
Initiated Coverage
6/2/2020Revance TherapeuticsHC Wainwright
Reiterated Rating
6/1/2020Ironwood PharmaceuticalsCredit Suisse Group
Lower Price Target
5/20/2020Revance TherapeuticsMizuho
Reiterated Rating
5/11/2020Ironwood PharmaceuticalsHC Wainwright
Lower Price Target
5/7/2020Ironwood PharmaceuticalsCredit Suisse Group
Reiterated Rating
5/7/2020Ironwood PharmaceuticalsMorgan Stanley
Lower Price Target
4/30/2020Ironwood PharmaceuticalsWells Fargo & Company
Lower Price Target
4/16/2020Revance TherapeuticsStifel Nicolaus
Lower Price Target
4/15/2020Revance TherapeuticsNeedham & Company LLC
Reiterated Rating
4/15/2020Ironwood PharmaceuticalsMorgan Stanley
Lower Price Target
4/1/2020Revance TherapeuticsMizuho
Reiterated Rating
3/27/2020Revance TherapeuticsWilliam Blair
Reiterated Rating
3/27/2020Revance TherapeuticsHC Wainwright
Reiterated Rating
3/22/2020Revance TherapeuticsThe Goldman Sachs Group
Downgrade
3/5/2020MorphicCowen
Reiterated Rating
2/26/2020Revance TherapeuticsHC Wainwright
Reiterated Rating
2/25/2020Revance TherapeuticsPiper Sandler
Boost Price Target
2/25/2020Revance TherapeuticsNeedham & Company LLC
Boost Price Target
1/28/2020Ironwood PharmaceuticalsHC Wainwright
Reiterated Rating
1/21/2020Ironwood PharmaceuticalsHC Wainwright
Reiterated Rating
9/13/2019Ironwood PharmaceuticalsCowen
Set Price Target
8/13/2019MorphicBMO Capital Markets
Boost Price Target
8/12/2019MorphicCowen
Reiterated Rating
7/31/2019Ironwood PharmaceuticalsWedbush
Boost Price Target
7/22/2019MorphicJefferies Financial Group
Initiated Coverage
7/22/2019MorphicCowen
Initiated Coverage
7/22/2019MorphicWells Fargo & Company
Initiated Coverage
7/22/2019MorphicBMO Capital Markets
Initiated Coverage
7/10/2019Ironwood PharmaceuticalsCredit Suisse Group
Reiterated Rating
6/24/2019Ironwood PharmaceuticalsHC Wainwright
Set Price Target
5/6/2019Ironwood PharmaceuticalsWedbush
Reiterated Rating
5/3/2019Ironwood PharmaceuticalsMorgan Stanley
Set Price Target
5/2/2019Ironwood PharmaceuticalsMizuho
Set Price Target
(Data available from 9/23/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.